Actinium Pharmaceuticals, Inc. (ATNM)
| Market Cap | 33.88M-30.5% |
| Revenue (ttm) | n/a |
| Net Income | n/a+127.6% |
| EPS | n/a+127.5% |
| Shares Out | 31.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,380 |
| Open | 1.09 |
| Previous Close | 1.07 |
| Day's Range | 1.06 - 1.10 |
| 52-Week Range | 0.73 - 1.74 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 11.07(+925.00%) |
| Earnings Date | n/a |
Insiders here have filed 7 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ATNM
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
$ATNM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ATNM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ATNM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ATNM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ATNM Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Recognized upfront payment | $35.00M | 33.33% |
| Other revenue | $35.00M | 33.33% |
| Non-refundable payment received | $35.00M | 33.33% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ATNM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ATNM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ATNM
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $936.93K |
| VXFVanguard Extended Market ETF | $321.68K |
| IWCiShares Micro-Cap ETF | $108.18K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $40.00K |
Estimated from each fund’s disclosed top holdings × AUM
ATNM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ATNM’s recent data — informational, not investment advice